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Abstract.  Rat sciatic nerve Schwann cells in culture 
respond to a limited range of mitogens,  including  glial 
growth factor, transforming growth factors beta-1 and 
beta-2 (TGF-fll, TGF-/~2),  some cell mem- 
brane-associated factors, and to agents such as cholera 
toxin and forskolin which raise intracellular  levels of 
cAME These responses require the presence of FCS, 
which exhibits little or no mitogenic activity in the ab- 
sence of other factors.  However, we recently found 
that forskolin greatly potentiates the mitogenic signal 
from TGFs-/~I and/32,  raising the possibility that 
cAMP might couple other factors to mitogenesis.  We 
have therefore screened a range of candidate mitogens 
using DNA synthesis assays. Other than TGFs-fl and 
glial growth factor, none of the factors tested were 
mitogenic in the presence of 10%  serum alone.  With 
the addition of forskolin, however, porcine PDGF, hu- 
man PDGF, acidic and basic FGF were potent mito- 
gens for rat Schwann cells,  stimulating DNA synthesis 
and increasing cell number.  Cholera toxin and 
dibutyrylcyclicAMP, but not 1,9-dideoxyforskolin, can 
substitute for forskolin indicating that the mitogenic 
effect is mediated via adenylyl cyclase activation.  Por- 
cine PDGF gave half-maximal  stimulation at  15 pM, 
and human PGDF an equivalent response at  1 nM. 
Basic FGF was half maximal at 5 pM, acidic FGF at 
1  nM. 
The recognition of PDGFs and FGFs as mitogens 
for Schwann cells has many implications for the study 
of Schwann cell proliferation in the development and 
regeneration of nerves, and in Schwann cell tumori- 
genesis. 
S 
CHWANN cells, the glial cells of the peripheral nervous 
system, surround all peripheral nerve axons, and in the 
case of myelinated  nerve fibers,  elaborate the myelin 
sheaths  necessary for fast impulse  conduction.  There are 
many important developmental  and functional  interactions 
between Schwann cells and axons. Of particular interest for 
this paper is the proliferation of Schwann cells in three con- 
texts.  During development, Schwann  cells proliferate  and 
migrate out along  newly formed axons,  surrounding  them, 
and myelinating  them in some cases (3, 32). If the nerve is 
injured,  through  mechanical  trauma, neurotoxins  or demy- 
elinating diseases for example, Schwann cells again prolifer- 
ate to restore the integrity of the Schwann cell sheath and aid 
regeneration  of functional  nerve  fibers  (1,  42).  Thirdly, 
Schwann cell tumors may arise on any peripheral  nerve,  as 
in  the  cases of Von  Recklinghausen's  neurofibromatosis, 
bilaterai  acoustic neurofibromatosis,  and spontaneous, non- 
hereditary acoustic neuromas (47). The origin and nature of 
the  factors  involved  in  these  proliferative  processes  are 
poorly understood. 
Attempts  to define the factors involved in Schwann cell 
proliferation  have  revealed positive  responses by various 
types of Schwann cell in culture to a limited range of mito- 
gens (38,  51),  including  a  few polypeptide growth factors 
(35), molecules derived from central and peripheral nervous 
system membranes (13, 28, 37, 39, 43, 44, 49, 53), and ana- 
logues of cAMP and agents, such as cholera toxin, that raise 
intracellular  levels of cAMP (36).  Gila maturation  factor, 
reported to be a rat Schwann cell mitogen, has recently been 
found to contain contaminants,  including  (FGF) ~ (7,  27). 
For the past ten years, glial growth factor (GGF) has been 
viewed as the only soluble polypeptide growth factor for rat 
sciatic nerve Schwann cells and was purified on the basis of 
this activity (8).  GGF,  a 31-kD basic polypeptide isolated 
from bovine pituitaries and present in the nervous system of 
higher vertebrates (26), has subsequently been implicated in 
the limb regeneration  of Urodele amphibians  (9).  In addi- 
tion, a GGF-like factor has been detected in extracts of hu- 
man acoustic neuromas (12). Four striking features of the re- 
sponses of rat sciatic nerve Schwann cells to mitogens were 
(a) that these cells grew extremely slowly in 10% FCS (dou- 
bling time "-'8 d) and incorporated very little 5'-[t25I]-iodo  - 
2'-deoxyuridine  ([~25I]-UdR) or [3H]thymidine during 48-h 
assays (33, 36);  (b) that GGF required serum for its mito- 
genic activity  (26);  (c) that a range  of well-known  soluble 
polypeptide growth factors (including  PDGF, FGF, EGF, 
and  nerve growth  factor),  pituitary  hormones,  neuropep- 
1. Abbreviations used in this paper: aFGF, acidic FGF; bFGF, basic FGF; 
dbcAMP, dibutyrylcAMP; FCP, fetal calf plasma; GGF, glial growth factor; 
hPDGE human PDGF; IL, intedeukin;  pPDGF, porcine  PDGF; PDGF- 
AA, PDGF with AA chain composition; PDGF-BB, PDGF with BB chain 
composition;  pPDGE porcine PDGF; TGF, transforming growth factor. 
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partially  purified  GGF  ([GGF-CM]  GGF-carboxymethyl 
cellulose fraction), in the presence of serum, would syner- 
gize with agents that stimulated intracellular cAMP (33, 35). 
Recently it has been found that transforming growth fac- 
tors (TGFs)/~1 and/~2 are mitogenic for rat sciatic nerve 
Schwann cells (40), suggesting that these cells may be less 
restricted in their responses to growth factors than previ- 
ously suggested. During attempts to establish the responses 
of rat sciatic nerve Schwann cells to purified soluble factors, 
we found that forskolin, a diterpene drug that reversibly acti- 
vates adenylyl cyclase with similar effects to cholera toxin 
(45), greatly potentiates the mitogenie signal from TGFs-/3 
(40),  raising the possibility that adenylyl cyclase agonists 
might couple other growth factors to mitogenesis and re- 
inforcing the idea that Schwann cells might respond to a 
wide range of soluble growth factors. As a result, we have 
screened,  using  incorporation of [~2sI]-UdR, a  variety of 
candidate mitogens  in  serum-containing medium,  in  the 
presence and absence of forskolin. This screening, coupled 
with measurements of  cell number and morphological obser- 
vations, has revealed two additional classes of growth factors 
to be mitogenic for rat sciatic nerve Schwann cells. 
Materials and Methods 
Materials 
Insulin,  NGF-7S,  NGF-2.5S,  prolactin,  follicle-stimulating  hormone, 
ACTH, vasopressin,  oxytocin, met-enkephalin, leu-enkephalin, substance- 
P, neurotensin, angiotensin-I, angiotensin-II, vasoactive intestinal peptide, 
somatostatin, bombesin, gastrin releasing peptide,  bradykinin, histamine, 
dopamine,  norepinephrine, epinephrine,  serotonin, gamma-amino-n-bu- 
tyric acid, glutamate, glycine, acetylcholine, ATE cholera toxin, isobutyl- 
methyixanthine, dibutyrylcAMP (dbcAMP), fatty acid-free BSA,  I-/~-D- 
arabinofuranosylcytosine, poly-D-lysine hydrobromide (Mr 30-70 kD), and 
rabbit complement were obtained from Sigma Chemical Co.  (St.  Louis, 
MO); porcine PDGF (pPDGF), human PDGF (hPDGF), acidic and basic 
FGF (aFGF and bFGF), TGFs-#I,  -/~2, interleukin-la (IL-lo0, IL-IB, IL-2, 
IL-3, IL-4, IL-6, tumor necrosis factor-~,  tumor necrosis factor-/~ (British 
Biotechnology  Ltd.,  Oxford,  England); insulin-like growth factor-I,  in- 
sulin-like growth factor-II (KabiGen AB, Stockholm, Sweden); batch tested 
FCS,  fetal calf plasma (FCP) (Imperial  Laboratories Ltd., Andover,  En- 
gland); tissue culture plastics (Costar,  Data Packaging Corp., Cambridge, 
MA); DME,  2.5%  trypsin in PBS,  and 0.05%  trypsin/0.02%  EDTA in 
modified  Puck's saline (Gibco Laboratories, Scotland);  collagenase  (type 
I) (Worthington Biochemical Corp., Freehold, NJ); forskolin,  1,9-dideoxy- 
forskolin, cholera toxin (Calbiochem-Behring  Corp., San Diego, CA); anti- 
Thy-l.l (Serotec  Ltd., Oxford, England); [l~I]-UdR (Amersbam Interna- 
tional, Amersham, England); rabbit anti-rat S-IO0 antibody (gift of Dr. R. 
Mirsky, University College,  London); recombinant human PDGF with BB 
chain composition (PDGF-BB)  and PDGF with AA chain composition 
(PDGF-AA)  (gift of Drs. S. M. Gale and C. George-Nascimento, Chiron 
Corp., Emeryville,  CA); EGF (gift of Dr. G. Pana~tou, Ludwig Institute 
for Cancer Research,  London); GGF-CM (0.13 mg/ml protein by Bio-Rad 
assay with gamma-globulin standard), prepared according to the method of 
Brockes (8) (gift of Dr. A. D. J. Goodearl, Ludwig Institute for Cancer Re- 
search). 
Preparation of  Schwann Cells 
Schwann cells from rat sciatic  nerves were isolated  essentially  using the 
method of Brockes et ai. (8, 11). Briefly, sciatic nerves were dissected from 
2-5-d-old Sprague-Dawley rat pups, dissociated with 0.1% collagenase and 
2.5%  trypsin in DME,  and plated into polylysine-coated  tissue culture 
flasks in DME, 10% FCS. After ,~24 h the medium was replaced with fresh 
medium containing 10 mM l-/~-D-arabinofuranosylcytosine.  3-4 d later the 
cells were washed and fed with DME, 10% FCS, 5 t~M forskolin, 0.5 t~g/ml 
GGF--CM. Once confluent, 2-3 d later, the cells were detached from the 
flask  with 0.05%  trypsin, 0.02%  EDTA  in modified  Puck's saline, and 
washed and treated with anti-Thy-l.l  and rabbit complement for 30 min to 
remove contaminating fibroblasts. Sehwann cells were grown in DME, 10% 
FCS, 5 #M forskolin, 0.5 t~g/ml GGF-CM, fed every second day, and pas- 
saged every 4-7 d  as described above.  The Sehwann cell cultures were 
>99% pure and contained <1% fibroblasts,  as determined by morphology 
and S-100 staining. 
DNA Synthesis Assay 
DNA synthesis in Schwann cells was assessed by measuring incorporation 
of [125I]-UdR, according to the method of Broekes (8). Cells were cultured 
in the absence of GGF-CM or forskolin for 2-3 d, then seeded into 96-well 
plates at 10,000 cells/well  in 100/~i/well  DME,  10% FCS or FCP. After 
overnight incubation, samples were added to the assay plates. Factors were 
prepared in 4 mM HCi or PBS, containing 1 mg/ml BSA (fatty acid free). 
Forskolin  stocks  were prepared in dimethyl suiphoxide.  All factors  were 
serially diluted in DME and added in a constant volume to give a total vol- 
ume of 120 t~l/well and the required final concentration. Dose responses of 
solvents alone had no effect (data not shown). The cells were then incubated 
with samples for48 h, 0.2 t~Ci/well [125I]-UdR being added for the last 24 
h. Medium was then aspirated, cells detached using 0.05% trypsin, 0.02% 
EDTA in modified Puck's saline, and harvested (Multimash 2000; Dynatech 
Laboratories Inc., Cbantilly,  VA) onto glass-fiber filter mats for counting 
(Gamma 5500; Beckman Instruments Inc., Palo Alto, CA). 
Measurement of Cell Proliferation 
24-well plates were prepared by coating with poly-t>-lysine, at 100/~g/ml 
water using 2.5 pg/cm  2 polylysine for 5 rain, followed by one wash with 
water and air drying.  Schwann cells were cultured for 3 d in the absence 
of forskolin or GGF-CM and seeded into the wells at a density of 60,000 
cells/well.  After overnight incubation, samples were added at a concentra- 
tion equivalent to that which gave maximal stimulation in the DNA synthe- 
sis assays (2.6 t~g/ml GGF-CM, 10 nM aFGE 100 pM bFGE 3 nM pPDGE 
3  nM hPDGF).  The cells were  incubated for 4  d,  photographed, tryp- 
sinized, and counted in an hemocytometer. 
Results 
Screening of Candidate Mitogens 
A range of soluble polypeptide growth factors, pituitary hor- 
mones, neuropeptides, and neurotransmitters to which rat 
Schwann cells might respond were assayed for their ability 
to stimulate DNA synthesis in the presence of 10% FCS with 
and without forskolin. In general, a wide range of concentra- 
tions was tested, and most factors were highly pure prepara- 
tions (Table I). GGF-CM (Fig.  1 A) and TGFs-/~ (Table I) 
were mitogenic in the presence of serum with and without 
forskolin, as previously reported (26,  33, 40).  Most of the 
factors tested in the presence or absence of forskolin gave no 
mitogenic  response,  in  general  agreement with  previous 
reports showing that Schwann cells respond to few mitogens 
(35, 38, 51). 
Forskolin Couples PDG  Fs and FGFs to Mitogenesis 
The addition of forskolin to the assay, however, revealed the 
potent mitogenic effects of particular PDGF isoforms, and 
also aFGF and bFGE The mitogenic response in the pres- 
ence of forskolin alone was generally in the range of 200- 
1,000 cpm, these low values being due to the use of FCS pre- 
screened for a low forskolin background, pPDGF (BB chain 
composition) gave half-maximal stimulation at ,,o15 pM and 
maximal activity at ,,o10 nM (Fig. 1 B). Recombinant human 
PDGF-BB, in which there is no possibility of contaminating 
A-chains, behaved similarly to pPDGF, reaching the same 
maximum stimulation as pPDGF (data not shown). In con- 
trast hPDGF (mainly AB chain composition) had not yet 
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Schwann Cells 
Factor  Concentration tested  Activity* 
TGF-~  1 
TGF-/~2 
pPDGF 
hPDGF 
PGDF-BB 
PDGF-AA 
aFGF 
bFGF 
EGF 
Insulin 
Insulin-like growth factor I 
Insulin-like growth factor II 
Nerve growth factor (2.5S) 
Nerve growth factor (7S) 
IL-la 
IL-I~ 
IL-2 
IL-3 
IL-4 
IL-6 
Tumor necrosis factor-~ 
Tumor necrosis factor-/~ 
Luteotrophic hormone 
Follicle stimulating hormone 
Adrenocorticotrophic hormone 
Vasopressin 
Oxytocin 
Met-enkephalin 
Leu-enkephalin 
Substance P 
Neurotensin 
Angiotensin-I 
Angiotensin-II 
Vasoactive intestinal  peptide 
Somatostatin 
Gastrin releasing peptide 
Bradykinin 
Histamine 
Dopamine 
Norepinephrine 
Epinephrine 
Serotonin 
Gamma amino butyric acid 
Glutamic acid 
Glycine 
Acetylcholine 
ATP 
100 fM-I  nM 
100 fM-I  nM 
300 fM-30 nM 
10 fM-3 nM 
3 pM-30 nM 
3 pM-30 nM 
10 fM-100 nM 
10 fM-1  nM 
40 fM-100 nM 
10 fM-100 nM 
1 pM-10 nM 
1 pM-10 pM 
400 fM-400 pM 
700 fM-7 nM 
1 fM-10 nM 
2  fM-20 nM 
700 fM-7 nM 
700 fM-7 nM 
700 fM-7 nM 
500 IM-5 nM 
10 pM-100  nM 
2 pM-20 nM 
1 pM-I  #M 
1 pM-I  ILM 
1 pM-I  nM 
1 pM-I  #M 
1 pM-I  #M 
1 pM-I  /zM 
1 pM-I  /~M 
670 fM-670 nM 
1 pM-I  /~M 
900 fM-900 nM 
900 fM-900 nM 
10 pM-10 nM 
10 pM-100  nM 
30 fM-100 nM 
10 pM-I  #M 
1 pM-I  #M 
5 pM-50 nM 
5 pM-5  ~M 
5 pM-5  ~M 
1 pM-I  ~M 
1 pM-I  ~M 
1 pM-I  ~M 
1 pM-1  ~M 
1 pM-1  ~M 
2 pM-2  ~M 
a, af 
a,  af 
af 
af 
af 
af 
af 
* -, no effect; a, active; af, active with forskolin. 
reached a maximum at 3 nM and was ,'o70-fold  less active 
than pPDGF (Fig.  1 B),  suggesting that the reduction  in 
potency was due to the A-chain component.  Since highly 
purified human PDGF contains variable and undetermined 
quantities of BB and AA chains (17),  we also tested recom- 
binant human PDGF-AA, which, although it is as highly ac- 
tive as pPDGF in mitogenic assays with Swiss 3T3 cells (our 
unpublished  results),  gave no  response  with  rat  Schwann 
cells in the presence of forskolin (Table I). 
aFGF  and  bFGF  were  also  strongly  mitogenic  for  rat 
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Figure 1.  DNA synthesis in rat sciatic nerve Schwann cells in the 
presence of GGF-CM,  PDGFs,  and  FGFs.  Factors  were added, 
with (closed symbols) or without (open symbols) 5 #M forskolin, 
to cells in DME, 10% FCS, in 96-well plates for 48 h. DNA synthe- 
sis was measured by incorporation of [t25I]-UdR  over the last 24 h. 
(A) GGF-CM; (B) pPDGF (m) or hPDGF (o); (C) bFGF (m) or 
aFGF (o). Each figure is a typical example of at least three separate 
experiments, where each value represents the mean of duplicate ob- 
servations not differing from the mean by >10%. 
Schwann cells in the presence of serum and forskolin (Fig. 
1 C). bFGF gave a half-maximal stimulation at ,x,5 pM and 
reached a maximum at 40-100 pM, whereas aFGF had not 
reached a clear maximum at 50 nM, and only gave a stimula- 
tion approaching the half maximal of bFGF at  1 nM (Fig. 
1 C). Interestingly, bFGF gave strong inhibition at concen- 
trations over 300  pM,  emphasizing the need to carry out 
mitogenic assays over a wide range of concentrations, aFGF 
was ,,o200-foid less active than bFGF, as has been found in 
other systems. 
The Response to PDGFs or FGFs Is Dependent upon 
Raised IntraceUular cAMP 
The  observation  that  forskolin  is  required  to  effect  the 
mitogenicity of PDGFs or FGFs suggests that cAMP may be 
the mediator of the required cooperation. However, forskolin 
is known to have effects other than the activation of adenylyl 
cyclase leading to a rise in intracellular cAMP (45), such as 
membrane perturbation and activation of ion channels (19), 
Davis and Stroobant PDGFs and FGFs Are Mitogens for Schwann  Cells  1355 inhibition of glucose transport, and desensitization of acetyl- 
choline receptors (21, 52). For these reasons we investigated 
whether the forskolin effect required for the mitogenicity of 
PDGFs or FGFs is due to the activation of adenylyl cyclase 
by using the forskolin analogue  1,9-dideoxyforskolin. This 
analogue, which fails to activate adenylyl cyclase but shows 
similar biochemical properties to forskolin in other respects 
(45,  19, 21, 52), is unable to support the stimulation of DNA 
synthesis by PDGFs or FGFs (Fig. 2). Similarly, other agents 
that are known to cause a rise in intracellular cAMP, such 
as cholera toxin or dbcAMP also couple FGFs or PDGFs to 
mitogenesis (Fig.  2). 
Plasma Can Replace Serum for the 
Mitogenic Response 
Since these results indicate that PDGFs in the presence of 
elevated cAMP are mitogenic, and since TGFs-~ have previ- 
ously  been  shown  to  be mitogenic  for rat  Schwann  cells 
(40), the use of serum in mitogenic assays raises two ques- 
tions. Firstly, although FCS prescreened for low background 
activity was used in the screen, could levels of platelet-de- 
rived factors have influenced the results? Secondly, although 
cAMP has previously been considered to be mitogenic (36), 
could this response be due to coupling with the PDGF and 
TGF-B present in the FCS? Schwann cells exposed to FGFs 
or PDGFs in the presence of FCP showed the same mito- 
genic responses as seen with FCS; giving no response in the 
presence of FCP alone and responses of the same shape and 
magnitude as in Fig. 1 when incubated with FCP plus forsko- 
lin; and demonstrating that a platelet factor(s) is not the se- 
rum constituent required for response to the soluble growth 
factors, and that FCP equals FCS  in providing factors re- 
quired for maintenance and the responses to growth factors 
and forskolin (data not shown). The background DNA syn- 
thesis of the cells with forskolin was higher with FCS than 
FCP, suggesting that the serum-derived platelet factors may 
be required for the mitogenic effect of forskolin. Fig. 3 shows 
the mitogenic response to cholera toxin (Fig. 3 A) or forsko- 
lin (Fig. 3 B) in the presence of FCP and two lots of FCS. 
Both lots of FCS give a higher response than FCP but one 
is particularly mitogenic in the presence of 0.5 #M forskolin, 
which is characteristic of TGF-/~ (40),  a major component 
in bovine sera. A small response still remains in the presence 
of FCP, which may be due to a failure to remove all platelets 
from the plasma or before some released their contents, but 
also possibly due to the  secretion of some growth factors 
by the  Schwann  cells themselves (34).  However, the data 
show that cAMP elevating agents are largely dependent upon 
platelet factors from serum for their mitogenic activity, sug- 
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Figure 2.  DNA  synthesis  in 
rat sciatic nerve Schwann cells 
exposed to PDGF-BB (3 nM), 
hPDGF  (3  nM),  bFGF  (50 
pM), aFGF (10 nM), or GGF- 
CM  (2.6 #g/ml) in the pres- 
ence of DME,  10% FCP, and 
either blank (B), 5 #M 1,9-di- 
deoxyforskolin (i), 5 p.M for- 
skolin (@), 100/.tM dbcAMP 
([]), or 100 pM cholera toxin (D) for 48 h. Errors  =  SEM, n  = 
4. One of two experiments. 
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Figure 3. DNA synthesis in rat sciatic nerve Schwann cells after in- 
cubation  for 48  h  in  DME and,  (<9) 10%  FCP, (o)  10%  FCS 
(screened  for  low background  growth),  or (a)  10%  FCS  (high 
background), in the presence of dose responses to either (A) chol- 
era toxin or (B) forskolin. Each value represents the mean of dupli- 
cate observations not differing from the mean by >10%,  and are 
typical of three separate experiments. 
gesting that cAMP may be mitogenic for rat Schwann cells 
only in the presence of platelet factors such as PDGFs and 
TGFs-B, or with FGFs. 
Effects of PDGFs and FGFs on Cell Proliferation 
To  establish  whether  these  highly  suggestive  changes  in 
[~25I]-UdR incorporation reflect a  true mitogenic response 
by the cells, it was necessary to observe the effects of PDGFs 
and FGFs in the presence of forskolin on cell proliferation. 
In  agreement  with  previous  studies  of  rat  sciatic  nerve 
Schwann cell growth in the presence of forskolin we found 
it necessary to coat tissue culture plastic surfaces with poly- 
lysine  to  maintain  the  adherence  of  dividing  cells  over 
periods of more than a few days (33). Furthermore, because 
our studies with FCP led to lower background growth than 
in serum,  10%  FCP was used in place of 10%  FCS.  Table 
II presents changes in cell number after exposure of Schwann 
cells to factors, at concentrations estimated to be optimal in 
Table II. Cell Growth with Forskolin plus FGFs or PDGFs 
Addition  Cells/Well*~ 
No  addition  83,500  +  6,500 
GGF  249,000  +  1,750 
pPDGF  207,500  -t-  15,500 
hPDGF  107,500  +  3,000 
aFGF  213,000  +  6,000 
bFGF  143,500  -I-  8,500 
* p <  0.05,  g _+  SEM (n  =  4) one of two experiments. 
Schwann  cells were  seeded  into  24-well  plates,  coated  with  polylysine in 
DME,  10%  FCP at a  density of 60,000  cells/well. After 24  h  incubation, 
growth factors were added to a final concentration of 2.6 p,g/ml GGF-CM,  I0 
uM aFGF,  100 pM bFGF, 3 nM pPDGF, 3 nM hPDGF, 5 p.M forskolin, and 
incubated for a  further 4  d  at  37°C,  I0%  CO:.  The cells were  then  pho- 
tographed and detached by trypsinization for counting in an hemocytometer. 
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PDGF and aFGF stimulated increases in cell number which 
were, respectively, 149 and 155 % above the background for- 
skolin value, while bFGF and hPDGF gave increases of 72 
and 29%,  respectively. The lower responses may be due to 
differences  in  the  requirements  of the  cells  for  each  in- 
dividual growth factor over the longer incubation time of 4  d 
compared to the DNA synthesis assays (Fig.  1) of only 2 d. 
The lower response to bFGF, however, may also be partly 
due to the more narrow effective concentration range of this 
factor and the use of a concentration close to the upper limit 
of this range.  Although the presence of the polylysine sub- 
stratum  introduces  an  additional  variable,  which  possibly 
influences the responses to soluble growth factors, the data 
nevertheless confirm the DNA synthesis results above and 
that  pPDGE  hPDGE  aFGE  and  bFGF  are  capable  of 
stimulating Schwann cell proliferation. 
The Morphology of Cells Growing in PDGFs or FGFs 
Schwann cells in culture express a  range of different mor- 
phologies, especially in response to mitogens. In addition to 
the characteristic bipolar, aligned cells, a second morphol- 
ogy may be seen that is flatter, darker,  fibroblast-like, and 
more frequent in the presence of forskolin or cholera toxin. 
The  cells  may also take on  a  very spindly appearance in 
serum-free medium (10, 51).  Fig. 4 shows the appearance of 
the  cells  when  stimulated  with  GGF-CM,  aFGF,  bFGE 
pPDGE or hPDGF in the presence of FCP and forskolin for 
4 d. Serum and forskolin alone resulted in the Schwann cells 
Figure 4.  Phase-contrast microscopy of rat sciatic nerve Schwann cells after growing on polylysine-coated 24-well plates for 4 d in the 
presence of DME,  10% FCE 5/~M forskolin, and (a) no addition,  (b) 2.6/~g/ml GGF-CM, (c) l0 nM aFGE (d)  100 pM bFGE (e) 3 
nM pPDGE and (f) 3 nM hPDGE Bar, lO0/~m. 
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phology (Fig. 4 a), whereas the addition of FGFs (Fig. 4, 
c and d) or PDGFs (Fig. 4, e and f) caused increases in cell 
density and a morphology similar to that seen upon stimula- 
tion with GGF-CM and forskolin (Fig. 4 b) (33), showing 
the characteristic alignment and packing of Schwann cells, 
with long bipolar processes. 
Discussion 
These results show that pPDGF, hPDGE bFGF, and aFGF, 
which are inactive in the presence of serum alone and there- 
fore have not previously been recognized as mitogens for rat 
sciatic nerve Schwann cells, are highly mitogenic for these 
cells  when administered with  forskolin,  cholera toxin or 
dbcAMP. 
It is clear that rat sciatic nerve Schwaun cells are not mito- 
genically responsive to all three PDGF isoforms, BB, AB, 
and  AA,  as  are  some  other  cell  types  (18).  The potent 
Schwann  cell response to both pPDGF  and  recombinant 
PDGF-BB, the weaker response to hPDGF, and the nonmi- 
togenicity of recombinant  PDGF-AA,  suggest  that  these 
cells only respond mitogenically to dimers containing at 
least one PDGF B-chain. Despite an apparent consensus that 
there are at least two classes of PDGF receptor, a B-chain- 
specific class and an A-chain- and B-chain-specific class, 
there are substantial differences within the field concerning 
the subunit composition of receptors (18, 46), which prevent 
further conclusions about the nature of PDGF receptors on 
the Schwann cells used in these experiments. 
bFGF was 200-fold more active than aFGF in our assays, 
similar to observations with other cell types (6). The signifi- 
cance, however, of any differences in activity is unclear at 
present, as the two species have very different tissue distribu- 
tions 06), and because aFGF appears to be equally active 
in  some circumstances when stabilized with heparin,  al- 
though the physiological relevance of this effect is unclear 
(15).  In the past there have been conflicting reports as to 
whether FGF is a mitogen for Schwann cells, bFGF has been 
reported to be weakly mitogenic for rat Schwann cells (39), 
however, we and others (35, 42) have failed to observe any 
effect at concentrations of up to  l  nM bFGF and 40 nM 
aFGF in the absence of forskolin. Such apparent discrepan- 
cies may be due to differences in assay conditions, and in 
growth factor or cell preparations. In contrast, the response 
of mouse dorsal root ganglion Schwann cells to FGF and se- 
rum mitogens is undisputed (24), and PDGF stimulates cell 
proliferation in human fetal dorsal root ganglion Schwann 
cells (55).  Some of these responses are apparently due to 
differences between species, or in tissue origin..IntraceUular 
levels of cAMP, or part of the pathway initiated by cAMP, 
may control the responsiveness of the cells to PDGFs and 
FGFs,  and higher endogenous levels in mouse and human 
Schwann cells may explain why they respond to these factors 
without the need for an additional increase in cAMP concen- 
tration. 
The effects of forskolin detected in our screen suggested 
that cAMP has an important role to play in Schwann cell re- 
sponses to growth factors, as it does for example in Swiss 
3T3 cells (39). The results showing that the forskolin ana- 
logue 1,9-dideoxyforskolin, which does not activate adenylyl 
cyclase, is unable to couple PDGFs or FGFs to mitogenesis, 
strongly suggest that the role of forskolin is to raise intracel- 
lular cAMP. This is further strengthened by the observation 
that another agent acting via this pathway,  cholera toxin, is 
able to mimic forskolin, and dbcAMP is also effective. In 
view of these results it might be expected that physiological 
agents capable of raising intracellular cAMP might couple 
PDGFs and FGFs to mitogenesis. Vasoactive intestinal pep- 
tide, secretin, and ~-adrenergic agonists (norepinephrine, 
epinephrine)  have  been  shown  to  raise  cAMP  levels  in 
Schwann cells (54).  None of these,  however, was able to 
potentiate the activity of GGF-CM in our assays, even in the 
presence  of the  phosphodiesterase inhibitor  3-isobutyl-1- 
methylxanthine (50 #M) (our unpublished results). It is not 
clear whether this reflects an absence of receptors for the 
neuropeptides and adrenergic catecholamines in our Schwann 
cell preparations, or if a particular time of onset, duration, 
or level of intracellular cAMP is necessary for synergy with 
GGF-CM. However, clearly this is a promising experimental 
system in which to study the interactions between the cAMP 
generating pathways and those of the polypeptide growth 
factors. 
Recognition that the platelet factors PDGF and TGFs-/~ 
are mitogens for rat Schwann cells draws attention to a prob- 
lem in the common use of serum in mitogenic assays. Our 
results show that although these cells do not require platelet 
factors for their responses to PDGFs, FGFs, and GGF-CM, 
the mitogenicity of adenylyl cyclase activators is highly de- 
pendent upon the presence of platelet factors, and thus it is 
likely that forskolin, cholera toxin, or dbcAMP are not mito- 
gens in the absence of growth factors.  It remains for the 
mode of control exerted by cAMP over the Schwann cell re- 
sponse to the FGFs and PDGFs, and secondly, for the nature 
of the factor(s) still remaining undefined in FCP, which are 
required by the Schwann cells in order for them to respond 
to these factors (35), to be determined. 
Our observations using cultured cells suggest that PDGFs 
and FGFs may stimulate Schwann cell proliferation in vivo 
in situations where the cells are exposed to a second factor, 
or set of environmental conditions, that raises the intracellu- 
lar levels of CAMP. In turn, these factors should now be con- 
sidered in the processes of nerve development, myelination, 
regeneration,  and  Schwann  cell  tumorigenesis.  The  en- 
sheathment and myelination of new axons during develop- 
ment begins with the proliferation of Schwann cells upon 
contact with the axon. In vitro experiments have established 
that membrane preparations from both the central and pe- 
ripheral nervous system are mitogenic for Schwann cells, but 
that axolemmal membranes and PC12 membranes require 
the presence of serum. Although the evidence is not conclu- 
sive, a rise in cAMP does occur after stimulation with PC12 
or dorsal root ganglion neuron-derived membranes (37), and 
cholera toxin does not synergize with axolemmal membranes 
in Schwann cell mitogenesis assays, suggesting that some of 
the membrane mitogens may act via cAMP (38, 49). In view 
of our results, the mitogenic signal from those membranes 
requiring the presence of  serum may be due to a combination 
of serum platelet-derived factors and an increase in cAMP 
induced by the membrane mitogen. Interestingly, the expres- 
sion of antigens associated with myelination by Schwann 
cells also appears to be dependent upon cAMP, since their 
level of expression diminishes upon removal of axonal con- 
tact but is restored by agents which raise cAMP (20, 29, 50). 
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sue repair after injury, being released by platelets, endothe- 
lial cells, mesenchymal cells, and macrophages at sites of in- 
jury  and  inflammation.  The absence  of leader  sequences 
characteristic  of secreted  proteins  from the  FGFs  makes 
their involvement uncertain, although it is possible they play 
a role after cell damage or unknown secretory mechanisms. 
Macrophages are known to infiltrate the sites of nerve injury 
and their experimental exclusion from injured  nerves pre- 
vents the degradation of myelin and proliferation of Schwann 
cells that occurs after injury (5, 31).  This suggests that their 
presence is essential for the generation of the mitogenic sig- 
nal and an increase in cAMP does occur within 6-24 h of 
a crushing injury, concurrent with the appearance of mac- 
rophages.  Although  it is not clear what causes the rise in 
cAMP, it is known that macrophages secrete a mitogen for 
Schwann cells upon ingestion of myelin fragments (2, 4). 
Furthermore, activated  macrophages are capable of produc- 
ing PDGFs,  FGFs,  and agents such as prostaglandins that 
may raise cAMP levels in cells (14, 48). It is possible then, 
that macrophage-derived PDGFs and FGFs contribute to the 
stimulation of Schwann cell proliferation after nerve injury. 
Schwann cells in vitro may promote their growth through 
the autocrine production of growth factors (34).  Similarly, 
Schwann cells in vivo may promote growth in schwannomas 
through the autocrine production of PDGFs or FGFs, partic- 
ularly  in  association  with  conditions  raising  intracellular 
cAME  In  support of this possibility,  mRNA for FGF has 
been detected in acoustic neuromas (30), and a group of pitu- 
itary tumors that has a constitutively active adenylyl cyclase 
has recently been identified (25). 
Our observations  concerning  the  ability  of forskolin to 
couple PDGFs and FGFs to stimulate Schwann cell prolifer- 
ation, together with the previously documented stimulation 
by forskolin of GGF and TGFs-fl directed mitogenesis (40), 
could be of relevance to the clinical treatment of demyelinat- 
ing diseases or nerve injury, since physiological repair mech- 
anisms in these diseases may involve the local production of 
one or more of these factors. The possibility of forskolin hav- 
ing therapeutic applications in these areas is further strength- 
ened by positive results in stimulating amphibian and mam- 
malian peripheral nerve regeneration (22,  23). 
In conclusion we have  shown that PDGFs and FGFs are 
mitogens for rat Schwann cells in vitro, and that their inter- 
actions with cAMP are potentially important for Schwann 
cell proliferation in a number of contexts. A variety of fur- 
ther studies will be of interest, including the determination 
of how cAMP controls responses to growth factors, compari- 
sons of the responses of rat Schwann cells with other periph- 
eral and central nervous system glial cell types, and the rele- 
vance of our observations to human Schwann cell biology 
and pathology in vivo. 
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